ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Renal C3 complement component: feed forward to diabetic kidney disease [PDF]
, 2015 BACKGROUND: Diabetic nephropathy is the main cause of end-stage renal disease and has reached epidemic proportions. METHODS: Comprehensive genomic profiling (RNAseq) was employed in the ZS (F1 hybrids of Zucker and spontaneously hypertensive heart ...
Dominguez, Jesus H. +3 more
core +2 more sources
Activation of Hypoxia-Inducible Factors Prevents Diabetic Nephropathy [PDF]
, 2014 Lina Nordquist +7 more
openalex +1 more source
Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy [PDF]
, 2023 Seyyedeh Mina Hejazian +4 more
openalex +1 more source
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner +10 more
wiley +1 more source
Angiotensin-Converting Enzyme (ACE) 2 Overexpression Ameliorates Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison with ACE Inhibition [PDF]
, 2010 Chun Xi Liu +11 more
openalex +1 more source
Abstract #1595981: Changes in Fibroblast Growth Factor-23 and the Klotho Protein Axis in Diabetic Nephropathy [PDF]
, 2023 Nozimakhon Nazarova +7 more
openalex +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
Food Frontiers, EarlyView.The diagram of the mechanism of action by which UroA regulates RF. ABSTRACT The global prevalence and mortality rates associated with chronic kidney disease (CKD) have been on a continuous rise over recent decades. Renal fibrosis (RF) serves as a critical factor in the progression of CKD to end‐stage renal disease.
Xue Wu +8 more
wiley +1 more source
Suadian Acacia Gerrardii: Antidiabetic Effect in Rats Suffering from Diabetic Nephropathy and DNA Fingerprinting Using ISSR [PDF]
, 2020 Adil Aldhahrani
openalex +1 more source